Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC — Stella

stellabeta Find trials matched to me Trial Match

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC — Stella

Recruiting

Back to Hepatocellular Carcinoma Non-resectable trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(1 site)

China

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Large-scale testing

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment target

~427 participants

Started

November 2022

Primary completion

October 2026

Age range

18 Years – 75 Years

Last updated May 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov